These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25959722)

  • 21. Correlated NOS-Imu and myf5 expression by satellite cells in mdx mouse muscle regeneration during NOS manipulation and deflazacort treatment.
    Anderson JE; Vargas C
    Neuromuscul Disord; 2003 Jun; 13(5):388-96. PubMed ID: 12798794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
    Griggs RC; Miller JP; Greenberg CR; Fehlings DL; Pestronk A; Mendell JR; Moxley RT; King W; Kissel JT; Cwik V; Vanasse M; Florence JM; Pandya S; Dubow JS; Meyer JM
    Neurology; 2016 Nov; 87(20):2123-2131. PubMed ID: 27566742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proof-of-concept validation of the mechanism of action of Src tyrosine kinase inhibitors in dystrophic mdx mouse muscle: in vivo and in vitro studies.
    Sanarica F; Mantuano P; Conte E; Cozzoli A; Capogrosso RF; Giustino A; Cutrignelli A; Cappellari O; Rolland JF; De Bellis M; Denora N; Camerino GM; De Luca A
    Pharmacol Res; 2019 Jul; 145():104260. PubMed ID: 31059789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Review of Deflazacort for Patients With Duchenne Muscular Dystrophy.
    Bylo M; Farewell R; Coppenrath VA; Yogaratnam D
    Ann Pharmacother; 2020 Aug; 54(8):788-794. PubMed ID: 32019318
    [No Abstract]   [Full Text] [Related]  

  • 25. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.
    Gehrig SM; van der Poel C; Hoeflich A; Naim T; Lynch GS; Metzger F
    Growth Horm IGF Res; 2012 Apr; 22(2):69-75. PubMed ID: 22424862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF-α activation and ameliorates muscle function and morphology in mdx mice.
    Messina S; Bitto A; Aguennouz M; Vita GL; Polito F; Irrera N; Altavilla D; Marini H; Migliorato A; Squadrito F; Vita G
    Neuromuscul Disord; 2011 Aug; 21(8):579-89. PubMed ID: 21658942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nuclear magnetic resonance spectroscopy study of muscle growth, mdx dystrophy and glucocorticoid treatments: correlation with repair.
    McIntosh L; Granberg KE; Brière KM; Anderson JE
    NMR Biomed; 1998 Feb; 11(1):1-10. PubMed ID: 9608583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arginine butyrate: a therapeutic candidate for Duchenne muscular dystrophy.
    Vianello S; Yu H; Voisin V; Haddad H; He X; Foutz AS; Sebrié C; Gillet B; Roulot M; Fougerousse F; Perronnet C; Vaillend C; Matecki S; Escolar D; Bossi L; Israël M; de la Porte S
    FASEB J; 2013 Jun; 27(6):2256-69. PubMed ID: 23430975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy.
    Angelini C; Peterle E
    Acta Myol; 2012 May; 31(1):9-15. PubMed ID: 22655511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models.
    Liu G; Lipari P; Mollin A; Jung S; Teplova I; Li W; Ying L; More V; Lennox W; Yeh S; McGann E; Moon YC; Rice C; Huarte E; Gruszka B; Ray B; Goodwin E; Buckendahl P; Yurkow E; Braughton B; Narasimhan J; Welch E; Voronin G; Weetall M
    Hum Mol Genet; 2024 Jan; 33(3):211-223. PubMed ID: 37819629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
    Balaban B; Matthews DJ; Clayton GH; Carry T
    Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Melatonin improves muscle function of the dystrophic mdx5Cv mouse, a model for Duchenne muscular dystrophy.
    Hibaoui Y; Reutenauer-Patte J; Patthey-Vuadens O; Ruegg UT; Dorchies OM
    J Pineal Res; 2011 Sep; 51(2):163-71. PubMed ID: 21486366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy.
    Biggar WD; Skalsky A; McDonald CM
    J Neuromuscul Dis; 2022; 9(4):463-476. PubMed ID: 35723111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial.
    Shieh PB; Mcintosh J; Jin F; Souza M; Elfring G; Narayanan S; Trifillis P; Peltz SW; Mcdonald CM; Darras BT;
    Muscle Nerve; 2018 Nov; 58(5):639-645. PubMed ID: 30028519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
    Moxley RT; Ashwal S; Pandya S; Connolly A; Florence J; Mathews K; Baumbach L; McDonald C; Sussman M; Wade C; ;
    Neurology; 2005 Jan; 64(1):13-20. PubMed ID: 15642897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suramin affects metalloproteinase-9 activity and increases β-dystroglycan levels in the diaphragm of the dystrophin-deficient mdx mouse.
    Taniguti AP; Matsumura CY; Rodrigues-Simioni L; Santo Neto H; Marques MJ
    Muscle Nerve; 2012 Nov; 46(5):810-3. PubMed ID: 23055317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center.
    Marden JR; Freimark J; Yao Z; Signorovitch J; Tian C; Wong BL
    J Comp Eff Res; 2020 Feb; 9(3):177-189. PubMed ID: 31922454
    [No Abstract]   [Full Text] [Related]  

  • 38. Curcumin alleviates dystrophic muscle pathology in mdx mice.
    Pan Y; Chen C; Shen Y; Zhu CH; Wang G; Wang XC; Chen HQ; Zhu MS
    Mol Cells; 2008 Jun; 25(4):531-7. PubMed ID: 18460899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-RANKL Therapy Prevents Glucocorticoid-Induced Bone Loss and Promotes Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy.
    Jayash SN; Hamoudi D; Stephen LA; Argaw A; Huesa C; Joseph S; Wong SC; Frenette J; Farquharson C
    Calcif Tissue Int; 2023 Oct; 113(4):449-468. PubMed ID: 37470794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
    JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.